Bupropion for ADHD in Adolescents With Substance Use Disorder
Sponsor: National Institute on Drug Abuse (NIDA)
Listed as NCT00936299, this PHASE4 trial focuses on Attention Deficit Hyperactivity Disorder and Cannabis Use Disorder and remains completed. Sponsored by National Institute on Drug Abuse (NIDA), it has been updated 9 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE4
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2020 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Jan 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute on Drug Abuse (NIDA)
- University of Colorado, Denver
For direct contact, visit the study record on ClinicalTrials.gov .